{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:33:38Z","timestamp":1777901618690,"version":"3.51.4"},"reference-count":97,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T00:00:00Z","timestamp":1487203200000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Rheum Dis"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1111\/1756-185x.13001","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T07:23:34Z","timestamp":1487229814000},"page":"5-24","source":"Crossref","is-referenced-by-count":45,"title":["Pulmonary hypertension in connective tissue diseases: an update"],"prefix":"10.1111","volume":"20","author":[{"given":"Ramya","family":"Aithala","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology & Rheumatology; Christian Medical College; Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anoop G.","family":"Alex","sequence":"additional","affiliation":[{"name":"Department of Cardiology; Christian Medical College; Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debashish","family":"Danda","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology & Rheumatology; Christian Medical College; Vellore Tamil Nadu India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,16]]},"reference":[{"key":"10.1111\/1756-185X.13001-BIB0001|apl13001-cit-0001","doi-asserted-by":"crossref","first-page":"D42","DOI":"10.1016\/j.jacc.2013.10.032","article-title":"Definitions and diagnosis of pulmonary hypertension","volume":"62","author":"Hoeper","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/1756-185X.13001-BIB0002|apl13001-cit-0002","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"46","author":"Gali\u00e8","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0003|apl13001-cit-0003","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.37838","article-title":"Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension","volume":"65","author":"Valerio","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0004|apl13001-cit-0004","first-page":"746","article-title":"Updated clinical classification of pulmonary hypertension","volume":"63","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/1756-185X.13001-BIB0005|apl13001-cit-0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.13001-BIB0006|apl13001-cit-0006","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.100245","article-title":"Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies","volume":"37","author":"Avouac","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0007|apl13001-cit-0007","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0008|apl13001-cit-0008","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.13001-BIB0009|apl13001-cit-0009","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s10067-011-1896-x","article-title":"Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic","volume":"31","author":"Jansa","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"2 Suppl 76","key":"10.1111\/1756-185X.13001-BIB0010|apl13001-cit-0010","first-page":"31","article-title":"Pulmonary hypertension in systemic sclerosis: prevalence, incidence and predictive factors in a large multicentric Italian cohort","volume":"31","author":"Iudici","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0011|apl13001-cit-0011","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1378\/chest.08-3042","article-title":"Is pulmonary arterial hypertension really a late complication of systemic sclerosis?","volume":"136","author":"Hachulla","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1111\/1756-185X.13001-BIB0012|apl13001-cit-0012","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of Isolated Pulmonary Hypertension in Patients With Systemic Sclerosis and Limited Cutaneous Involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1111\/1756-185X.13001-BIB0013|apl13001-cit-0013","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.23187","article-title":"High N-Terminal Pro-Brain Natriuretic Peptide Levels and Low Diffusing Capacity for Carbon Monoxide as Independent Predictors of the Occurrence of Precapillary Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis","volume":"58","author":"Allanore","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0014|apl13001-cit-0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3899\/jrheum.090697","article-title":"Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension","volume":"37","author":"Shah","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0015|apl13001-cit-0015","first-page":"1424","article-title":"Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study","volume":"42","author":"Riccieri","year":"2013","journal-title":"Rheumatology"},{"key":"10.1111\/1756-185X.13001-BIB0016|apl13001-cit-0016","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.autrev.2012.07.010","article-title":"Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy","volume":"12","author":"Ruiz-Irastorza","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1111\/1756-185X.13001-BIB0017|apl13001-cit-0017","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/rheumatology\/kep203","article-title":"Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus","volume":"48","author":"Prabu","year":"2009","journal-title":"Rheumatology"},{"key":"10.1111\/1756-185X.13001-BIB0018|apl13001-cit-0018","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.revmed.2011.01.002","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus","volume":"32","author":"Arnaud","year":"2011","journal-title":"Rev Med Interne"},{"key":"10.1111\/1756-185X.13001-BIB0019|apl13001-cit-0019","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00296-012-2525-y","article-title":"Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population","volume":"33","author":"Xia","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1111\/1756-185X.13001-BIB0020|apl13001-cit-0020","first-page":"918","article-title":"Pulmonary hypertension in systemic lupus erythematosus","volume":"16","author":"Simonson","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0021|apl13001-cit-0021","first-page":"836","article-title":"Noninvasive assessment of systolic pulmonary artery pressure in systemic lupus erythematosus: retrospective analysis of 93 patients","volume":"28","author":"Fois","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0022|apl13001-cit-0022","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/kes430","article-title":"Prevalence of pulmonary hypertension in an unselected, mixed connective tissue disease cohort: results of a nationwide, Norwegian cross-sectional multicentre study and review of current literature","volume":"52","author":"Gunnarsson","year":"2013","journal-title":"Rheumatology"},{"key":"10.1111\/1756-185X.13001-BIB0023|apl13001-cit-0023","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1161\/01.CIR.68.6.1182","article-title":"Cardiovascular manifestations of mixed connective tissue disease in adults","volume":"68","author":"Alpert","year":"1983","journal-title":"Circulation"},{"key":"10.1111\/1756-185X.13001-BIB0024|apl13001-cit-0024","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/00005792-198403000-00003","article-title":"A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease","volume":"63","author":"Sullivan","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/1756-185X.13001-BIB0025|apl13001-cit-0025","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/1529-0131(199905)42:5<899::AID-ANR8>3.0.CO;2-L","article-title":"Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings","volume":"42","author":"Burdt","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0026|apl13001-cit-0026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.13001-BIB0027|apl13001-cit-0027","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1186\/ar4051","article-title":"Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study","volume":"14","author":"Ngian","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/1756-185X.13001-BIB0028|apl13001-cit-0028","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/acr.22121","article-title":"Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry","volume":"66","author":"Chung","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1111\/1756-185X.13001-BIB0029|apl13001-cit-0029","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1002\/art.38029","article-title":"A systematic review and meta-analysis","volume":"65","author":"Lef\u00e8vre","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0030|apl13001-cit-0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"10.1111\/1756-185X.13001-BIB0031|apl13001-cit-0031","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.24267","article-title":"Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease","volume":"60","author":"Mathai","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0032|apl13001-cit-0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0033|apl13001-cit-0033","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.autrev.2015.11.012","article-title":"Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: a PRISMA-compliant systematic review and meta-analysis","volume":"15","author":"Qian","year":"2016","journal-title":"Autoimmune Rev"},{"key":"10.1111\/1756-185X.13001-BIB0034|apl13001-cit-0034","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1378\/chest.12-2396","article-title":"Systemic sclerosis-associated pulmonary arterial hypertension","volume":"144","author":"Chaisson","year":"2013","journal-title":"Chest"},{"key":"10.1111\/1756-185X.13001-BIB0035|apl13001-cit-0035","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/1756-185X.13001-BIB0036|apl13001-cit-0036","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1172\/JCI2261","article-title":"The binding of some human antiendothelial cell antibodies induces endothelial cell apoptosis","volume":"101","author":"Bordron","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1111\/1756-185X.13001-BIB0037|apl13001-cit-0037","first-page":"462","article-title":"Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension","volume":"25","author":"Negi","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0038|apl13001-cit-0038","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur Respir J"},{"issue":"6 Suppl 86","key":"10.1111\/1756-185X.13001-BIB0039|apl13001-cit-0039","first-page":"S-133","article-title":"The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis","volume":"32","author":"Morrisroe","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0040|apl13001-cit-0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"Dorfm\u00fcller","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1111\/1756-185X.13001-BIB0041|apl13001-cit-0041","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1183\/09059180.00003811","article-title":"Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus","volume":"20","author":"Johnson","year":"2011","journal-title":"Eur Respir Rev"},{"key":"10.1111\/1756-185X.13001-BIB0042|apl13001-cit-0042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000093846","article-title":"A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease","volume":"213","author":"Fujimoto","year":"2006","journal-title":"Dermatology"},{"key":"10.1111\/1756-185X.13001-BIB0043|apl13001-cit-0043","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1002\/art.30541","article-title":"Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival","volume":"63","author":"Humbert","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0044|apl13001-cit-0044","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/art.38172","article-title":"Recommendations for Screening and Detection of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0045|apl13001-cit-0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13075-015-0517-5","article-title":"A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis","volume":"17","author":"Hao","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1111\/1756-185X.13001-BIB0046|apl13001-cit-0046","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1164\/rccm.200811-1691OC","article-title":"Accuracy of doppler echocardiography in the hemodynamic assessment of pulmonary hypertension","volume":"179","author":"Fisher","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0047|apl13001-cit-0047","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1378\/chest.126.4.1313","article-title":"New formula for predicting mean pulmonary artery pressure using systolic pulmonary artery pressure","volume":"126","author":"Chemla","year":"2004","journal-title":"Chest"},{"issue":"1","key":"10.1111\/1756-185X.13001-BIB0048|apl13001-cit-0048","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3899\/jrheum.090661","article-title":"Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group","volume":"37","author":"Kowal-Bielecka","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0049|apl13001-cit-0049","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1164\/rccm.200604-547OC","article-title":"Tricuspid annular displacement predicts survival in pulmonary hypertension","volume":"174","author":"Forfia","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0050|apl13001-cit-0050","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/art.34501","article-title":"Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension","volume":"64","author":"G\u00fcnther","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0051|apl13001-cit-0051","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1093\/eurheartj\/ehi891","article-title":"Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension","volume":"27","author":"Williams","year":"2006","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1111\/1756-185X.13001-BIB0052|apl13001-cit-0052","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1183\/09031936.00074309","article-title":"Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension","volume":"35","author":"Mathai","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0053|apl13001-cit-0053","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/eurheartj\/ehq170","article-title":"Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension","volume":"31","author":"Montani","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1111\/1756-185X.13001-BIB0054|apl13001-cit-0054","first-page":"1366","volume-title":"Kelly's Textbook of Rheumatology","author":"Boin","year":"2012","edition":"9"},{"key":"10.1111\/1756-185X.13001-BIB0055|apl13001-cit-0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.080447","article-title":"Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma","volume":"36","author":"Garin","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0056|apl13001-cit-0056","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/1756-185X.13001-BIB0057|apl13001-cit-0057","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2147\/DDDT.S29916","article-title":"Stability and microbiological properties of a new formulation of epoprostenol sodium when reconstituted and diluted","volume":"6","author":"Lambert","year":"2012","journal-title":"Drug Des Dev Ther"},{"key":"10.1111\/1756-185X.13001-BIB0058|apl13001-cit-0058","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost in severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.13001-BIB0059|apl13001-cit-0059","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0060|apl13001-cit-0060","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. A double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1111\/1756-185X.13001-BIB0061|apl13001-cit-0061","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0062|apl13001-cit-0062","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/1756-185X.13001-BIB0063|apl13001-cit-0063","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1378\/chest.126.2.420","article-title":"Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"issue":"9","key":"10.1111\/1756-185X.13001-BIB0064|apl13001-cit-0064","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/1756-185X.13001-BIB0065|apl13001-cit-0065","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0735-1097(03)00463-7","article-title":"Beraprost therapy for pulmonary arterial hypertension","volume":"41","author":"Barst","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl A","key":"10.1111\/1756-185X.13001-BIB0066|apl13001-cit-0066","first-page":"A38","article-title":"Effect of selexipag on morbidity\/mortality in pulmonary arterial hypertension: results of the GRIPHON study","volume":"65","author":"McLaughlin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/1756-185X.13001-BIB0067|apl13001-cit-0067","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/1756-185X.13001-BIB0068|apl13001-cit-0068","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.13001-BIB0069|apl13001-cit-0069","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0070|apl13001-cit-0070","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Gali\u00e8","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/1756-185X.13001-BIB0071|apl13001-cit-0071","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension.Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"key":"10.1111\/1756-185X.13001-BIB0072|apl13001-cit-0072","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"key":"10.1111\/1756-185X.13001-BIB0073|apl13001-cit-0073","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.13001-BIB0074|apl13001-cit-0074","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Galie","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1111\/1756-185X.13001-BIB0075|apl13001-cit-0075","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","year":"2007","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1111\/1756-185X.13001-BIB0076|apl13001-cit-0076","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"key":"10.1111\/1756-185X.13001-BIB0077|apl13001-cit-0077","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","article-title":"Tadalafil therapy for pulmonary arterial hypertension","volume":"119","author":"Galie","year":"2009","journal-title":"Circulation"},{"key":"10.1111\/1756-185X.13001-BIB0078|apl13001-cit-0078","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0079|apl13001-cit-0079","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.13001-BIB0080|apl13001-cit-0080","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.13001-BIB0081|apl13001-cit-0081","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in PAH","volume":"45","author":"Galie","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0082|apl13001-cit-0082","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1183\/09031936.04.00028404","article-title":"Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2","volume":"24","author":"Humbert","year":"2004","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1111\/1756-185X.13001-BIB0083|apl13001-cit-0083","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0084|apl13001-cit-0084","first-page":"A965","article-title":"TRIUMPH I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension","volume":"177","author":"McLaughlin","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0085|apl13001-cit-0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Pulmonary Arterial Hypertension combination Study of Epoprostenol and Sildenafil (PACES) Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1111\/1756-185X.13001-BIB0086|apl13001-cit-0086","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"AMBITION Investigators. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/1756-185X.13001-BIB0087|apl13001-cit-0087","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0088|apl13001-cit-0088","doi-asserted-by":"crossref","first-page":"840A","DOI":"10.1378\/chest.10295","article-title":"Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 study","volume":"138","author":"Benza","year":"2010","journal-title":"Chest"},{"issue":"10","key":"10.1111\/1756-185X.13001-BIB0089|apl13001-cit-0089","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1111\/1756-185X.13001-BIB0090|apl13001-cit-0090","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1002\/art.22264","article-title":"Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension","volume":"54","author":"Schachna","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/1756-185X.13001-BIB0091|apl13001-cit-0091","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1161\/CIRCULATIONAHA.113.004526","article-title":"Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)","volume":"129","author":"Olsson","year":"2014","journal-title":"Circulation"},{"key":"10.1111\/1756-185X.13001-BIB0092|apl13001-cit-0092","first-page":"A2464","article-title":"Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)","volume":"189","author":"Preston","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/1756-185X.13001-BIB0093|apl13001-cit-0093","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3899\/jrheum.110765","article-title":"Warfarin in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. A Bayesian approach to evaluating treatment for uncommon disease","volume":"39","author":"Johnson","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1111\/1756-185X.13001-BIB0094|apl13001-cit-0094","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1183\/09031936.00039212","article-title":"Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension","volume":"41","author":"Henkens","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1111\/1756-185X.13001-BIB0095|apl13001-cit-0095","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/art.23303","article-title":"Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases","volume":"58","author":"Jais","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1111\/1756-185X.13001-BIB0096|apl13001-cit-0096","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1378\/chest.130.1.182","article-title":"Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension","volume":"130","author":"Sanchez","year":"2006","journal-title":"Chest"},{"key":"10.1111\/1756-185X.13001-BIB0097|apl13001-cit-0097","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/rheumatology\/kev097","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study","volume":"54","author":"Kommireddy","year":"2015","journal-title":"Rheumatology (Oxford)"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13001","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/1756-185X.13001\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T14:16:34Z","timestamp":1625494594000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13001","archive":["Portico"],"relation":{},"ISSN":["1756-1841"],"issn-type":[{"value":"1756-1841","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}